Oral MS drug fingolimod filed for approval in Japan
This article was originally published in Scrip
Executive Summary
In line with its earlier guidance, Mitsubishi Tanabe Pharma (MTP) has made a filing before the end of the year in Japan for the approval of its first-in-class oral multiple sclerosis drug fingolimod (FTY720).